Legend Biotech (NASDAQ:AMTI) Receives New Coverage from Analysts at BofA Securities
Investment analysts at BofA Securities assumed coverage on shares of Legend Biotech (NASDAQ:AMTI) in a report released on Tuesday, Briefing.com Automated Import reports. The firm set a “buy” rating and a $34.00 price target on the stock. BofA Securities’ price target suggests a potential upside of 30.02% from the company’s current price.
A number of other research analysts also recently issued reports on the company. Bank of America began coverage on Legend Biotech in a report on Tuesday. They issued a “buy” rating for the company. SVB Leerink initiated coverage on Legend Biotech in a report on Tuesday. They issued an “outperform” rating and a $32.00 target price for the company.
Legend Biotech stock opened at $26.15 on Tuesday. Legend Biotech has a 52 week low of $17.05 and a 52 week high of $31.84.
Applied Molecular Transport Inc develops biological therapeutics to treat autoimmune, metabolic, and inflammatory diseases.. The company develops submucosal biopharmaceuticals and bio-betters. Applied Molecular Transport Inc was incorporated in 2010 and is based in South San Francisco, California.
Featured Story: What is the FTSE 100 index?
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.